



ASX Announcement

4 November 2020

Invex to Present at Upcoming Small Caps Virtual Conference

Invex Therapeutics Ltd (Invex, ASX: IXC, or the Company) a clinical-stage biopharmaceutical company focused on the development and commercialisation of Presendin™ (Exenatide) for neurological conditions relating to raised intracranial pressure, today provides an opportunity for shareholders and investors to join an upcoming virtual presentation by Invex Executive Director Dr Tom Duthy, who will present at the NWR Virtual Small Caps Conference to be held on 4-6 November 2020.

Event: NWR Communications Virtual Small Caps Conference

Presenting: Dr Tom Duthy

Time/date: 12:30pm AEDT, Thursday 5 November 2020

The event is free and investors can register online to view the presentation here:
https://us02web.zoom.us/webinar/register/WN_lv797nT-T-uDF7ukmSurew

This release dated 4 November 2020 has been authorised for lodgement to ASX by the Board of Directors of Invex Therapeutics and lodged by Narelle Warren, Company Secretary.

ENDS

For more information, please contact:

Company/Investors

Dr Thomas Duthy
Executive Director
tduthy@invextherapeutics.com
+61 402 493 727

Media

Margie Livingston
Ignite Communications
margie@ignitecommunications.com.au
+61 438 661 131

To subscribe to Invex email alerts, please visit www.invextherapeutics.com and follow us on Twitter [@InvexThera_ASX](https://twitter.com/InvexThera_ASX)

About Invex Therapeutics Ltd

Invex is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure, such as Idiopathic Intracranial Hypertension (IIH), acute stroke and traumatic brain injury. Invex has trademarked its repurposed Exenatide as Presendin™. www.invextherapeutics.com.

About Idiopathic Intracranial Hypertension (IIH)

IIH features severely raised intracranial pressure which causes disabling daily headaches and can compress the optic nerve, causing permanent vision loss in 25% of those affected. The usual age of onset is 20-30 years, and it is most common in women who are obese. IIH is a rapidly growing orphan indication: its incidence has increased by more than 350% in the last 10 years.